<DOC>
	<DOCNO>NCT02258542</DOCNO>
	<brief_summary>The purpose study characterize safety profile benralizumab administration asthma patient complete one three predecessor study : D3250C00017 , D3250C00018 D3250C00020 .</brief_summary>
	<brief_title>A Safety Extension Study Evaluate Safety Tolerability Benralizumab ( MEDI-563 ) Asthmatic Adults Adolescents Inhaled Corticosteroid Plus LABA</brief_title>
	<detailed_description>After minimum 1200 patient enrol study , subsequent patient ( maximum 2200 total study ) , complete minimum 16 week , 40 week , study , give option transition open-label safety extension study , Study D3250C00037 ( MELTEMI ) . Adolescent patient , patient Japan South Korea , patient chooses enter Study D3250C00037 remain study IPD EOT FU .</detailed_description>
	<criteria>Inclusion criterion 1 . Informed consent ( and/or assent applicable locally ) study participation must obtain prior study related procedure perform ( local regulation follow determine assent/consent requirement child parent ( ) /guardian ( ) ) accord international guideline and/or applicable European Union guideline . 2 . Female male patient complete doubleblind treatment period predecessor study benralizumab match placebo . 3 . Women childbearing potential ( WOCBP ) must agree use effective form birth control throughout study duration 16 week last dose Investigational Product ( IP ) . 4 . For WOCBP : Have negative urine pregnancy test prior administration Investigational Product ( IP ) Visit 1 . 5 . All male patient sexually active must agree use double barrier method contraception ( condom spermicide ) first dose IP 16 week last dose . Exclusion criteria 1 . Any disorder include limited cardiovascular , gastrointestinal , hepatic , renal , neurological , musculoskeletal , infectious , endocrine , metabolic , haematological , psychiatric major physical impairment stable opinion Investigator could : Affect safety patient throughout study Influence finding study interpretation Impede patient 's ability complete entire duration study 2 . A helminth parasitic infection diagnose predecessor study either treat , incompletely treat failed respond standard care therapy 3 . Any clinically significant change physical examination , vital sign , electrocardiogram ( ECG ) , haematology , clinical chemistry , urinalysis predecessor study opinion investigator may put patient risk his/her participation study , may influence result study , interfere patient 's ability complete entire duration study 4 . Current malignancy malignancy develop predecessor study ( subject basal cell carcinoma , localize squamous cell carcinoma skin resect cure , situ carcinoma cervix treated/cured exclude ) . 5 . Receipt live attenuate vaccine within 30 day prior initiation treatment study , treatment period , 16 week ( 5 halflives ) last dose investigational product 6 . Receipt immunoglobulin blood product within 30 day prior Visit 1 7 . Planned major surgical procedure conduct study 8 . Previous participation present study 9 . Concurrent enrolment another clinical trial 10 . AstraZeneca staff involve planning and/or conduct study 11 . Employees study centre individual involve conduct study immediate family member individual 12 . Patients major protocol deviation predecessor study discretion Sponsor</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Asthma , Bronchial Diseases , Respiratory Tract Diseases , Lung Diseases , Obstructive Lung Diseases</keyword>
</DOC>